Metabolic
Cagrilintide
CagriSema (with semaglutide) · amylin · analog
An amylin-pathway weight-loss drug being trialled alongside semaglutide (as 'CagriSema') — promising phase-3 data, but not yet an approved standalone medicine.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Cagrilintide works on the amylin pathway, which affects appetite and satiety through a different mechanism than GLP-1 drugs. It's being developed mainly as a combination with semaglutide (branded CagriSema in trials), rather than as a standalone product.
Phase-3 trial data for the combination has shown meaningful additional weight loss over semaglutide alone. As of writing it is not yet an approved medicine — it remains in the regulatory approval pipeline.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Adds meaningful weight loss on top of semaglutide”
Supported by real phase-3 CagriSema trial data; full approval and long-term data are still pending.
Claim-level citation mapping is in progress.
“Works via a distinct amylin-receptor mechanism”
Mechanistically well characterised and consistent with trial results so far.
Claim-level citation mapping is in progress.
“A finished, ready-to-use retail product”
It isn't approved yet — anything sold now is unregulated and outside any clinical-trial safeguards.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not an approved medicine in the UK — still in clinical trials as of writing. No legal prescription route exists yet for cagrilintide or CagriSema.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Discussed mostly in the context of the CagriSema combination rather than alone, with genuine excitement about the trial results tempered by 'it's not approved yet' reminders.
Where they’re talking
- News & socialCagriSema trial headlines drive most of the interest.
- r/PeptidesDistinguished from standalone semaglutide/tirzepatide discussion.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency